Stifel Nicolaus Reiterates Buy Rating for ConvaTec Group (LON:CTEC)

ConvaTec Group (LON:CTEC)‘s stock had its “buy” rating reissued by equities research analysts at Stifel Nicolaus in a report issued on Wednesday,London Stock Exchange reports. They currently have a GBX 315 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 33.36% from the stock’s previous close.

A number of other research firms have also recently weighed in on CTEC. Peel Hunt reiterated an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a research note on Thursday, November 13th. Citigroup reiterated an “outperform” rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research note on Thursday, March 5th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th. Finally, Berenberg Bank upped their price target on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of GBX 319.

ConvaTec Group Stock Performance

ConvaTec Group stock traded down GBX 6.60 during mid-day trading on Wednesday, reaching GBX 236.20. 300,110,219 shares of the company’s stock were exchanged, compared to its average volume of 24,001,486. The firm has a market capitalization of £4.60 billion, a PE ratio of 27.47, a P/E/G ratio of 0.93 and a beta of 0.76. ConvaTec Group has a one year low of GBX 209.40 and a one year high of GBX 311.20. The company has a quick ratio of 0.96, a current ratio of 1.53 and a debt-to-equity ratio of 106.19. The business’s fifty day simple moving average is GBX 235.94 and its 200 day simple moving average is GBX 236.67.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.